All Stories

  1. Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids
  2. Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans
  3. A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes
  4. Developmental Expression of the Cytosolic Sulfotransferases in Human Liver
  5. Construction of a per- and polyfluoroalkyl substances (PFAS) screening library
  6. The Impact of Scaling Factor Variability on Risk-Relevant Pharmacokinetic Outcomes in Children: A Case Study Using Bromodichloromethane (BDCM)
  7. Application of epigenetic data in human health risk assessment
  8. Ontogeny of human hepatic CYP2C8 and CYP1A2
  9. FutureTox III: Bridges for Translation
  10. Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards
  11. Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models
  12. Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver
  13. Oxidative stress-responsive transcription factor NRF2 is not indispensable for the human hepatic Flavin-containing monooxygenase-3 (FMO3) gene expression in HepG2 cells
  14. Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny
  15. Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny
  16. Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin
  17. Use of the RISK21 roadmap and matrix: human health risk assessment of the use of a pyrethroid in bed netting
  18. Current Research and Opportunities to Address Environmental Asbestos Exposures
  19. Raising the Bar for Reproducible Science at the U.S. Environmental Protection Agency Office of Research and Development
  20. A 21st century roadmap for human health risk assessment
  21. Risk assessment in the 21st century: Roadmap and matrix
  22. Human Hepatic UGT2B15 Developmental Expression
  23. Tolerance to Acetaminophen Hepatotoxicity in the Mouse Model of Autoprotection Is Associated with Induction of Flavin-Containing Monooxygenase-3 (FMO3) in Hepatocytes
  24. Developmental expression of drug metabolizing enzymes: Impact on disposition in neonates and young children
  25. Toll-like receptor genetic variants are associated with Gram-negative infections in VLBW infants
  26. Hepatobiliary Disposition of 17-OHPC and Taurocholate in Fetal Human Hepatocytes: A Comparison with Adult Human Hepatocytes
  27. A TIR domain receptor–associated protein (TIRAP) variant SNP (rs8177374) confers protection against premature birth
  28. Amine Oxidases and Reductases
  29. Age-Dependent Expression of Human Drug-Metabolizing Enzymes
  30. A TLR5 (g.1174C > T) variant that encodes a stop codon (R392X) is associated with bronchopulmonary dysplasia
  31. Prenatal and Postnatal Expression of Glutathione Transferase ζ 1 in Human Liver and the Roles of Haplotype and Subject Age in Determining Activity with Dichloroacetate
  32. The NFKB1 (g.-24519delATTG) Variant is Associated with Necrotizing Enterocolitis (NEC) in Premature Infants
  33. Hepatic differentiation of amniotic epithelial cells
  34. Human and environmental health challenges for the next decade (2010–2020)
  35. Approaches for Assessing Risks to Sensitive Populations: Lessons Learned from Evaluating Risks in the Pediatric Population
  36. Human hepatic CYP2B6 developmental expression: The impact of age and genotype
  37. Differential regulation of human hepatic flavin containing monooxygenase 3 (FMO3) by CCAAT/enhancer-binding protein β (C/EBPβ) liver inhibitory and liver activating proteins
  38. Developmental Changes in Human Liver CYP2D6 Expression
  39. The ontogeny of drug metabolism enzymes and implications for adverse drug events
  40. Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression
  41. Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition
  42. Identification and Functional Analysis of a Novel Human CYP2E1 Far Upstream Enhancer
  43. Phase I Biotransformation Reactions-Flavin Monooxygenase
  44. Mechanisms Regulating HumanFMO3Transcription
  45. Ontogeny of human hepatic cytochromes P450
  46. Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic Variants
  47. Epirubicin Glucuronidation and UGT2B7 Developmental Expression
  48. Pharmacogenomics and the Future of Drug Therapy
  49. Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: II. Expression and Role of Flavin-Containing Monooxygenases and Peroxidases
  50. Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: I. Expression and Role of Cytochromes P450
  51. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: A case study with toluene
  52. Population-Based Analysis of Methadone Distribution and Metabolism Using an Age-Dependent Physiologically Based Pharmacokinetic Model
  53. Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3
  54. A Tiered Approach to Life Stages Testing for Agricultural Chemical Safety Assessment
  55. The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines
  56. Developmental Expression of Aryl, Estrogen, and Hydroxysteroid Sulfotransferases in Pre- and Postnatal Human Liver
  57. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development
  58. MOLECULAR MECHANISMS REGULATING HUMAN CYP4B1 LUNG-SELECTIVE EXPRESSION
  59. SP1 AND SP3 REGULATE BASAL TRANSCRIPTION OF THE HUMAN CYP2F1 GENE
  60. Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants
  61. DIFFERENCES IN FMO2*1 ALLELIC FREQUENCY BETWEEN HISPANICS OF PUERTO RICAN AND MEXICAN DESCENT
  62. Two distinct classes of CCAAT box elements that bind nuclear factor-Y/?-actinin-4: potential role in human CYP1A1 regulation
  63. NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of ethylene glycol
  64. NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of propylene glycol
  65. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine
  66. Developmental Expression of Human Hepatic CYP2C9 and CYP2C19
  67. Developmental Expression of the Major Human Hepatic CYP3A Enzymes
  68. Human Hepatic CYP2E1 Expression during Development
  69. PUBLICATION OF STAND-ALONE SINGLE NUCLEOTIDE POLYMORPHISM (SNP) DISCOVERY DATA
  70. Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6)
  71. Workshop Overview: Use of Genomic Data in Risk Assessment
  72. Biochemical and Clinical Aspects of the Human Flavin-Containing Monooxygenase Form 3 (FMO3) Related to Trimethylaminuria
  73. CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians
  74. Trichloroethylene Decreases Heat Shock Protein 90 Interactions with Endothelial Nitric Oxide Synthase: Implications for Endothelial Cell Proliferation
  75. Characterization of the Human LungCYP2F1Gene and Identification of a Novel Lung-specific Binding Motif
  76. Genetics and Susceptibility to Toxic Chemicals: Do You (or Should You) Know Your Genetic Profile?
  77. Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis
  78. Alternative Processing of the Human FMO6 Gene Renders Transcripts Incapable of Encoding a Functional Flavin-Containing Monooxygenase
  79. The Ontogeny of Human Drug-Metabolizing Enzymes: Phase II Conjugation Enzymes and Regulatory Mechanisms: Table 1
  80. The Ontogeny of Human Drug-Metabolizing Enzymes: Phase I Oxidative Enzymes: Table 1
  81. Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression
  82. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities
  83. GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO)
  84. Induction of cytochrome P450 1A1 gene expression, oxidative stress, and genotoxicity by carbaryl and thiabendazole in transfected human HepG2 and lymphoblastoid cells22Abbreviations: AhR, aryl hydrocarbon receptor; CAT, chloramphenicol acetyl transfera...
  85. Ethnic Differences in Human Flavin-Containing Monooxygenase 2 (FMO2) Polymorphisms: Detection of Expressed Protein in African-Americans
  86. Diflubenzuron, a Benzoyl-Urea Insecticide, Is a Potent Inhibitor of TCDD-Induced CYP1A1 Expression in HepG2 Cells
  87. Regulation of DHP receptor expression by elements in the 5′-flanking sequence
  88. Developmental regulation of the L-type calcium channel α1C subunit expression in heart
  89. ROLE OF CANONICAL GLUCOCORTICOID RESPONSIVE ELEMENTS IN MODULATING EXPRESSION OF GENES REGULATED BY THE ARYLHYDROCARBON RECEPTOR*
  90. Flavin-containing monooxygenase isoform 2: Developmental expression in fetal and neonatal rabbit lung
  91. A Genetic Polymorphism in the Regulatory Sequences of HumanCYP2E1:Association with Increased Chlorzoxazone Hydroxylation in the Presence of Obesity and Ethanol Intake
  92. Functional characterization of the human CYP1A1 negative regulatory element: modulation of Ah receptor mediated transcriptional activity
  93. Further Characterization of the Major and Minor RabbitFMO1Promoters and Identification of both Positive and Negative Distal Regulatory Elements
  94. Variation in Induction of Human Placental CYP2E1: Possible Role in Susceptibility to Fetal Alcohol Syndrome?
  95. Identification of Multiple Rabbit Flavin-Containing Monooxygenase Form 1 (FMO1) Gene Promoters and Observation of Tissue-Specific DNase I Hypersensitive Sites
  96. VARIATION IN INDUCTION OF PLACENTAL CYTOCHROME P4502E1: POSSIBLE ROLE IN SUSCEPTIBILITY TO FETAL ALCOHOL SYNDROME? • 484
  97. Differential expression and activity of flavin-containing monooxygenases in euryhaline and stenohaline flatfishes indicates potential osmoregulatory role
  98. Partial characterization of the human CYP1A1 negatively acting transcription factor and mutational analysis of its cognate DNA recognition sequence.
  99. Developmental regulation of flavin-containing monooxygenase (FMO) isoforms 1 and 2 in pregnant rabbit
  100. In vitro binding and functional studies comparing the human CYPIAI negative regulatory element with the orthologous sequences from rodent genes
  101. Characterization of hepatic flavin monooxygenase from the marine teleost turbot (Scophthalmus maximus L.)
  102. The Mammalian Flavin-Containing Monooxygenases: Molecular Characterization and Regulation of Expression
  103. A Nomenclature for the Mammalian Flavin-Containing Monooxygenase Gene Family Based on Amino Acid Sequence Identities
  104. Differences in 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin‐inducible CYP1A1 expression in human breast carcinoma cell lines involve altered trans‐acting factors
  105. Expression of CYP1A1 Gene in Patients With Lung Cancer: Evidence for Cigarette Smoke-Induced Gene Expression in Normal Lung Tissue and for Altered Gene Regulation in Primary Pulmonary Carcinomas
  106. Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P-450-dependent monooxygenase activities
  107. Altered Regulation of the Cytochrome P4501A1 Gene: Novel Inducer-Independent Gene Expression in Pulmonary Carcinoma Cell Lines
  108. Glucocorticoid regulation of the rat cytochrome P450c (P450IA1) gene: Receptor binding within intron I
  109. Production of growth factors related to fibroblast growth factor and platelet-derived growth factor by human embryonal carcinoma cells
  110. Identification of multiple regulatory elements on the human cytochrome P450IA1 gene
  111. Induction of cytochrome P-450IA1 gene expression in human breast tumour cell lines
  112. Interaction of the 4 S polycyclic aromatic hydrocarbon-binding protein with the cytochrome P-450c gene
  113. Aflatoxin B1-4-hydroxylase is associated with cytochrome P3-450 in C57BL6 mouse liver
  114. The molecular biology of the polycyclic aromatic hydrocarbon inducible cytochrome P-450; the past is prologue
  115. Implication of the "4S" polycyclic aromatic hydrocarbon binding protein in the transregulation of rat cytochrome P-450c expression
  116. Demonstration of microsomal oxygenation of the benzo ring of 6-nitrobenzo[a]pyrene by thin-layer chromatography
  117. Molecular induction by phenobarbital of a rat hepatic form of cytochrome P-450: Expression of a 4-kilobase messenger RNA
  118. Inhibition of metabolism-mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma (line p815) cells
  119. The molecular cloning of cytochrome P-450c information
  120. EVIDENCE FOR INHIBITORY COMPLEXES FORMED WITH CYTOCHROME P-450 AND A METABOLITE OF 1,1-DISUBSTITUTED HYDRAZINES
  121. The role of Pi in glycolytic inhibition of calcium ion uptake by ELD ascites tumor cells